No Record Found
Sector
PharmaceuticalsOpen
₹188Prev. Close
₹187.25Turnover(Lac.)
₹2.93Day's High
₹190Day's Low
₹186.152 Week's High
₹396.9552 Week's Low
₹170Book Value
₹36.49Face Value
₹10Mkt Cap (₹ Cr.)
230.94P/E
30.85EPS
6.07Divi. Yield
0.26No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 13.24 | 13.71 | 10 | 10 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 24.76 | 14.19 | -13.07 | -17.58 |
Net Worth | 38 | 27.9 | -3.07 | -7.58 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 25.09 | 16.35 | 17.95 | 32.66 |
yoy growth (%) | 53.46 | -8.92 | -45.02 | -71.71 |
Raw materials | -14.8 | -9.06 | -25.38 | -28.15 |
As % of sales | 58.98 | 55.43 | 141.36 | 86.19 |
Employee costs | -2.49 | -2.61 | -2.96 | -2.77 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 1.41 | -1.8 | -53.37 | -26.41 |
Depreciation | -0.85 | -1.07 | -1.19 | -1.19 |
Tax paid | 0 | 0.1 | 0.31 | 0.19 |
Working capital | 2.96 | 8.78 | -54.83 | -23.02 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 53.46 | -8.92 | -45.02 | -71.71 |
Op profit growth | -744.32 | -99.36 | 124.45 | 321.48 |
EBIT growth | -233.46 | -97.82 | 144.81 | 251.42 |
Net profit growth | -183.08 | -96.78 | 102.35 | 79.09 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 |
|---|---|---|
Gross Sales | 70.1 | 54.41 |
Excise Duty | 0 | 0 |
Net Sales | 70.1 | 54.41 |
Other Operating Income | 0 | 0 |
Other Income | 1.22 | 0.52 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,784.15 | 91.59 | 4,28,077.35 | 564.22 | 0.9 | 4,511.27 | 99.24 |
Divis Laboratories Ltd DIVISLAB | 6,453.65 | 68.15 | 1,71,324.13 | 696 | 0.46 | 2,660 | 578.26 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,729.85 | 59.15 | 1,26,229.4 | 597 | 0.16 | 2,707 | 249.83 |
Cipla Ltd CIPLA | 1,526.35 | 23.72 | 1,23,294.16 | 1,210.53 | 1.05 | 4,495.16 | 411.56 |
Dr Reddys Laboratories Ltd DRREDDY | 1,250.1 | 19.33 | 1,04,335.99 | 387.3 | 0.64 | 4,602.9 | 377.56 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman / Executive Director / M D / Promoter
Ashwin Khemka
Executive Director
Srivardhan Ashwani Khemka
Independent Non Exe. Director
Mrunmai M Sarvankar
Independent Non Exe. Director
Monika Amit Singhania
Independent Non Exe. Director
Abhay Shah
Company Sec. & Compli. Officer
Ravikumar Bogham
205 P N Khotari Indl Estate,
LBS Marg Bhandup (West),
Maharashtra - 400078
Tel: 91-22-67290900
Website: http://www.sanjivani.co.in
Email: corporate@sanjivani.co.in; info@sanjivani.co.in, s
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: paytm.ipo@linkintime.co.in
Summary
Sanjivani Paranteral Ltd is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decad...
Read More
Reports by Sanjivani Paranteral Ltd
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.